PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Prothena Reports First Quarter Financial Results
Phase 1 Clinical Trial Initiated in April for NEOD001 in AL Amyloidosis Patients
View HTML
Toggle Summary First Patient Dosed in Phase I Study of Prothena's Therapeutic Antibody for Treatment of AL Amyloidosis
NEOD001 Enters Clinic With Orphan Designation and Potential to Meet Significant Unmet Need
View HTML
Toggle Summary Prothena Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Research and Development Update
Company Advances Pipeline With Strong Capital Position Following 2012 Spin-Off NEOD001 to Enter Clinic in Early 2013 DUBLIN, Ireland, March 28, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for
View HTML
Toggle Summary Prothena Announces Appointments of Chief Medical Officer and Chief Financial Officer
DUBLIN, Ireland, March 25, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced that two senior executives have joined the
View HTML
Toggle Summary Prothena to Report Fourth Quarter and Full Year 2012 Financial Results and Host Webcast and Conference Call on March 28, 2013
DUBLIN, Ireland, March 21, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced that it will report its fourth quarter and full
View HTML
Toggle Summary Prothena Announces Appointment of Biotech Pioneer to Board of Directors
DUBLIN, Ireland, March 19, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq: PRTA ), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced the appointment of Christopher S.
View HTML
Toggle Summary Prothena Achieves Orphan Drug Status in EU for Lead Program NEOD001
Potential Treatment for Systemic Amyloidoses Also Has US Designation
View HTML
Toggle Summary Prothena to Ring NASDAQ Stock Market Opening Bell
DUBLIN, Ireland, Feb. 13, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced that its President and Chief Executive Officer,
View HTML
Toggle Summary Prothena Announces Addition of Industry Veterans to Board of Directors
Richard T. Collier and Shane Cooke Join Board of Directors
View HTML
Toggle Summary Prothena Begins Trading on NASDAQ Global Market Under Symbol "PRTA"
Company Completes Successful Separation and Share Distribution From Elan
View HTML
Toggle Summary Prothena to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
Prothena to Present at the Lazard Capital Markets 9th Annual Healthcare Conference South San Francisco, CA, November 13, 2012 – Prothena Corporation, a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today
View HTML
Toggle Summary Elan Announces Plan to Spin-Off Discovery Science And Neotope Biosciences to Shareholders
Elan Announces Plan to Spin-Off Discovery Science And Neotope Biosciences to Shareholders Creates two independent, unique companies Transaction aligns assets, timelines, and risk/reward Elan to become immediately profitable and a high growth company Targeting $1.00 earnings per share by 2015 with
View HTML